Androgen deprivation therapy that targets AR is the primary treatment for metastatic PC and has shown therapeutic benefits for numerous patients, but patients inevitably develop into castration-resistant PC after androgen deprivation therapy [6, 7]. The gene discussed is AR; the disease is pachyonychia congenita.